Study details
Enrolling now
Platform Trial for Atopic Dermatitis
Novartis Pharmaceuticals
NCT IDNCT06947993ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
224
Study length
about 3.6 years
Ages
18–100
Locations
22 sites in AL, AR, CA +9
About this study
Researchers are testing a treatment called GHZ339 and a placebo in adults with moderate to severe atopic dermatitis. The trial will last about 1 year and involve approximately 224 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take GHZ339
- 2.Take Placebo
PhasePhase 2
Primary goalChange from baseline in the Eczema Area and Severity Index (EASI) score at Week 16
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16
Body systems
Dermatology